SMN1 and metabolic syndrome: A study by Deguise et al. reported that 37.5% of patients with primarily SMA types 1 and 2 and an average age of 3.8 years had an increased risk of developing dyslipidemia, and there was evidence of hepatic steatosis in their pathological specimens.